ENABLE-2 Open Call raising international interest


“We welcome the great international interest shown in our platform", states Anders Karlén, coordinator of ENABLE-2 that in a recent call for proposals received applications from six European countries.

Anders Karlén, koordinator för ENABLE-2
Anders Karlén, coordinator of ENABLE-2, Uppsala University

As ENABLE-2 – a platform supporting projects throughout the early stages of antibacterial drugs development – was granted continued funding from the Swedish Research Council, an open call was announced in order to add new projects to the platform portfolio. At the time, coordinator Anders Karlén expressed hope to implement European initiatives into ENABLE-2, and when the call ended 8 January, programs from six countries had submitted applications.

Anders Karlén and Diarmaid Hughes, ENABLE-2
Anders Karlén and Diarmaid Hughes, ENABLE-2

“The need for new antibiotics is urgent, and a larger geographical coverage will without a doubt increase our chances of extracting the greatest possible value. We have now received green light to proceed with projects at publicly funded European universities and thus welcome the great international interest shown in our platform,” states Anders Karlén, Professor of computer-based pharmaceutical design at Uppsala University.

An independent committee will now review the received applications with the aim to bring additional projects into ENABLE-2 as soon as possible. The platform is currently supporting four projects, two at the Swedish companies QureTech Bio AB and Thioredoxin Systems AB, and two at Uppsala University's Faculty of Pharmacy.


  • ENABLE-2 is a national platform that offers project support in the development of antibacterial drugs.
  • ENABLE-2 is coordinated at the Faculty of Pharmacy, Uppsala University.



Anders Karlén, Professor
Faculty of Pharmacy

Text: Magnus Alsne, photo: Mikael Wallerstedt

More news

Last modified: 2024-04-04